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ABSTRACT 
Introduction Liver cirrhosis is increasing worldwide and associated with high 
mortality.  Precise estimates of cause-specific mortality compared to the general population, 
by underlying aetiology, are lacking. Such information may demonstrate areas where 
therapeutic interventions can be targeted. 
Method We identified from the linked Clinical Practice Research Datalink (CPRD) and 
English Hospital Episode Statistics adults with an incident diagnosis of liver cirrhosis linked 
to the Office for National Statistics between 1998 and 2009. Age-matched controls from the 
CPRD general population were selected. We calculated the cumulative incidence (adjusting 
for competing risks) and excess risk of death by 5-years from diagnosis for different causes 
of death, stratified by aetiology and stage of disease.  
Results 5118 patients with cirrhosis were matched to 152,903 controls. Amongst 
compensated patients, the 5-year excess risk of liver-related death was higher than that of 
any other cause of death for all patients except those of unspecified aetiology. For example, 
those of alcohol aetiology had 30.8% excess risk of liver-related death (95%CI 27.9%, 
33.1%) compared to 9.9% excess risk of non-liver related death. However, patients of 
unspecified aetiology had a higher excess risk of non-liver related compared to liver-related 
death (10.7% vs. 6.7%). This was due to a high excess risk of non-liver neoplasm death 
(7.7%, 95%CI 5.9%, 9.5%). All decompensated patients had a higher excess of liver-related 
mortality than any other cause. 
 Conclusion In order to reduce associated mortality amongst people with liver cirrhosis, 
patients’ care pathways need to be tailored depending on aetiology and stage of disease. 
3 
 
3 
 
Study Highlights 
 
 
What is the current knowledge 
 
 Liver cirrhosis is increasing in the UK more than the top 4 diagnosed cancers and is 
associated with comparable poor survival. 
 
 Contemporary knowledge about the excess cause of death in patients with liver 
cirrhosis compared to the general population and how  this varies by aetiology is 
lacking. 
 
 No previous study on the subject has adjusted for competing risks which may lead to 
overestimates of cause-specific mortality. 
 
What is new here 
 Five-year excess risk of liver-related death is higher than that of any other cause of 
death for all compensated patients except those of unspecified aetiology.  
 
 Of all compensated patients, those with alcoholic cirrhosis have the highest excess 
risk of liver-related death. 
 
 Compensated patients of unspecified aetiology have a higher excess of non-liver 
neoplastic death than that of any other cause of death, by 5-years post diagnosis. 
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INTRODUCTION 
 
Cirrhosis of the liver is increasing worldwide at an alarming rate.[1]  In the UK the increase is 
faster than the four most common diagnosed cancers (breast, bowel, lung, prostate).[2] 
Mortality in people with cirrhosis is high, with 5-year survival rates reported to be similar to 
that of bowel cancer.[3] However, contemporary knowledge of what people with cirrhosis die 
from and how this varies by aetiology of their cirrhosis is lacking. Such information can be 
important to demonstrate areas where premature mortality could be reduced and guide 
evidence-based practice in patient follow-up. For example, a recent matched cohort study of 
patients experiencing a gastrointestinal (GI) bleed showed that over half the excess risk of 
death (i.e. the risk of death in cases compared to that of controls) was due to non-GI 
comorbidity, warranting non-GI assessment after a bleeding episode.[4] To date, the excess 
cause of death of patients with liver cirrhosis of all aetiologies estimated from a population-
based study has not been determined. Studies previously attempting to describe this have 
been either uncontrolled [5-7] or limited to reporting the relative mortality compared to an 
external comparator.[8-9] 
 
Current evidence in the UK, based on studies which commenced over 20 years ago, 
suggests that over half of people with cirrhosis die due to liver-related causes and those of 
alcohol aetiology are at higher risk of dying from liver-related death compared to those of 
non-alcohol aetiology.[6,8] However, the main limitation of previous papers is their hospital-
based setting that can lead to an overestimate of mortality. This is because these patients 
are likely to have more severe disease than patients with cirrhosis who are ambulatory. In 
addition, none of the authors have adjusted for competing risks (i.e. taken into account that 
patients may die due to other causes before dying from the cause of death of interest). This 
can lead to an overestimate of risk of death for each specific cause of death investigated.[10] 
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There is consequently a need for unbiased estimates of cause-specific mortality by aetiology 
of disease that can be used in a clinical setting to allow appropriate allocation of resource 
and ensure optimal patient care. The aim of this study is to use nationwide linked electronic 
routine healthcare data from primary and secondary care alongside national death registry 
data to report such estimates. 
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METHODS  
 
Study design 
We used population-based routinely collected electronic healthcare data from primary and 
secondary care registries in England to identify newly diagnosed cases of cirrhosis and 
linked Office for National Statistics (ONS) death registry data to determine cause and date of 
death. 
Primary care data  
The Clinical Practice Research Datalink (CPRD) is a longitudinal electronic database 
consisting of anonymised primary care records for over 10 million patients in the UK, 
collected since 1987. Data are coded using the Read code system.[11]  Participating 
practices are assigned an up to standard (UTS) date on completion of regular audits 
confirming data quality and completeness; patient-level data are also assessed.[12] The 
CPRD has previously been shown to be representative of the population of the UK.[13] 
Secondary care data 
The Hospital Episodes Statistics (HES) database comprises statutory records of all 
admissions (excluding outpatients) conducted in NHS hospitals and independent treatment 
centres in England, since 1989. For each period of time under the care of a consultant, a 
patient is assigned a primary diagnosis and up to 19 secondary diagnoses, coded using the 
ICD-10 (International Classification of Diseases, tenth revision), and/or up to 24 recorded 
procedures coded using the OPCS4 (Office of Population, Censuses and Surveys’ 
classification of surgical operations and procedures, fourth revision). Linked HES data are 
available for patients registered at consenting CPRD practices in England. Characteristics of 
patients in linked practices do not differ from those in non-linked practices.[14] 
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Death registry data  
The ONS provides death registry data for CPRD practices that are linked to the HES. The 
data consist of date of death and underlying cause of death obtained from death certification 
and completed according to World Health Organisation guidelines,[15] coded using 
International Classification of Diseases versions 9 (ICD-9) and 10 (ICD-10). 
 
Study population 
We have described the study population in detail previously.[2] In brief, we defined cirrhosis 
in primary care if a person had a record containing a Read code for cirrhosis, oesophageal 
varices and/or portal hypertension in the CPRD. This code list has been previously validated 
using medical notes.[16]  We developed code lists for cirrhosis diagnosis in secondary care 
from ICD-10 and OPCS4 codes. More than 90% of patients with a diagnosis in secondary 
care were reported to have supportive evidence of liver cirrhosis, either on their death 
certificate, in their primary care records or in the free text section of their primary care 
records.[2] For each patient we assigned the date of diagnosis as the first date associated 
with a Read or ICD-10/OPCS4 code for cirrhosis. Incident diagnoses in either CPRD or HES 
for patients (≥18years) were identified between January 1998 and December 2009.  
 
Aetiology 
For each patient, we searched all medical records for evidence of viral hepatitis, 
autoimmune and metabolic diseases. We have described the diagnostic codes used for 
each aetiology in detail previously.[2] Aetiology was ascribed in an hierarchical fashion of 
viral hepatitis, autoimmune or metabolic disease and alcoholic cirrhosis.  All remaining 
patients with no recorded aetiology were defined as having unspecified aetiology. Although 
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patients may have a record of more than one type of underlying disease, using four mutually 
exclusive groups minimises the loss of power in the analysis of these subgroups. 
 
Stage of disease 
We defined stages of disease, within one year from diagnosis, as agreed at the Baveno IV 
consensus conference.[17] For the analyses in this paper we grouped stages 1 and 2 
(cirrhosis with or without non-bleeding oesophageal varices, with no ascites) as 
compensated cirrhosis and stages 3 and 4 (cirrhosis with ascites and/or bleeding 
oesophageal varices) as decompensated cirrhosis.   
 
Causes of death 
We used the underlying cause of death code provided by the ONS, derived using 
standardised guidelines from the information available on death certificates.[18] Where 
necessary we mapped ICD-9 codes to ICD-10 codes; if mapping was not possible the cause 
of death was considered missing. Causes of death were categorised using the main ICD-10 
chapter headings as follows: liver (K70-K77,) which include alcoholic liver disease, toxic liver 
disease, hepatic failure, chronic hepatitis, fibrosis and cirrhosis of liver, other inflammatory 
liver diseases, other diseases of liver and liver disorders in diseases classified elsewhere; 
additionally malignant neoplasm of liver and intrahepatic bile ducts C22 which includes 
hepatocellular carcinoma (C22.0),, oesophageal and gastric varices (I85, I864 and I982); 
non-liver neoplasm (C00-D48 excluding C22);circulatory (I00-I99, excluding: I85, I864, I982) 
and respiratory (J00-J99). All other causes of deaths or missing ICD codes were categorised 
as ‘Other’.  
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Comparison group 
Controls were selected from the general population (patients from CPRD practices who did 
not have a liver cirrhosis diagnosis). We calculated a random pseudo-diagnosis date during 
the incident study period by selecting a random date between the registration start and end 
dates. Age was then calculated at this date and controls aged 18 years and onwards at the 
time of pseudo-diagnosis were included. Thirty controls were frequency matched to each 
case by age at diagnosis within 5 year age bands.  
 
Statistical analysis 
We excluded patients whose diagnosis of cirrhosis occurred on the same day as death. We 
described patient characteristics by aetiology (exposure) and used chi-squared tests for 
significance testing. The five grouped causes of death were the principal outcomes. 
Crude mortality rates 
Person-time at risk commenced at diagnosis of cirrhosis or pseudo-diagnosis date and 
ended at date of death or censoring of the patient record (earliest of date patient left the 
practice or last data collection date: 30th December 2010 or liver transplant date). Cause-
specific mortality rates were calculated by dividing the number of deaths due to each cause 
by the total person years of follow-up.  Rates were calculated for each major subgroup, and 
hepatocellular carcinoma specifically, for both cases and those without liver cirrhosis.  
Adjusted analysis 
As stated previously, conventional survival analysis provides probabilities of surviving a 
particular cause of death, say cancer, in the hypothetical world where it is not possible to die 
from anything else, say myocardial infarction. [19,20]. In contrast, competing risks theory 
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allows us to calculate real world probabilities where a patient is not only at risk of dying from 
a specific cause but also from any other cause of death. To adjust for this bias, we 
determined the cumulative incidence function (i.e. the predicted cumulative risk of death) by 
5 years from diagnosis for each specific cause of death. The 5-year cut-off point was used 
as the majority of deaths had occurred by then. The cumulative incidence function adjusts 
for competing risks by calculating the cumulative probability of dying from a specific cause at 
each time point having survived to that time without a death from any other cause. We 
derived the cumulative incidence from baseline survival functions and estimates of 
instantaneous hazards from cause-specific Cox proportional regression models, a well-
established approach.[10,21,22] The models were adjusted for age and sex, as we 
considered these to be a priori confounders. We stratified the cumulative incidence of death 
by aetiology and whether patients were compensated or decompensated at diagnosis. 
We calculated the excess risk of death for each specific cause as the difference between the 
cumulative incidence of death for cases and the cumulative incidence of death for those 
without liver cirrhosis; 95% confidence intervals were calculated by bootstrapping (50 
iterations). The cumulative incidence of death, and excess risk, for each cause of death was 
plotted using stacked graphs by aetiology sub-group. Stata version 12/MP4 was used for all 
statistical analyses.  
Subgroup analysis 
We identified patients’ last smoking record as the latest but not closer than 6 months before 
diagnosis (pseudo-diagnosis date for those without liver cirrhosis). Smoking status was 
classified as ‘ever-smoker’ (current/ex-smoker), ‘non-smoker’ or ‘missing’. We then 
determined whether the excess risk of death differed between ever-smokers and non-
smokers. 
RESULTS 
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Study population 
Our cohort consists of 5118 patients with an incident diagnosis of liver cirrhosis frequency 
matched on age to 152,903 people without liver cirrhosis. The median follow-up was 1.88 
[IQR 0.40, 4.27] and 3.13 [IQR 1.38, 6.14] years for those with and without liver cirrhosis, 
respectively. Age, sex, and stage of disease varied significantly by aetiology subgroup, 
p<0.001, (Table 1). Particularly decompensation around diagnosis was more prevalent 
amongst patients of alcohol and unspecified aetiology (48.2% and 45.4% respectively) than 
amongst the other aetiology subgroups (autoimmune/metabolic 27.1%; viral hepatitis 
32.6%). 
The comparison group had a smaller proportion of men and a smaller proportion of ever-
smokers than the study cohort. The proportion of ever-smokers amongst those without liver 
cirrhosis was similar to that of the unspecified aetiology subgroup (Table 1).  
 
Crude mortality rates 
Table 2 shows the crude mortality rates for those with and without liver cirrhosis. Overall, for 
people with cirrhosis, there were 2546 (49.7%) deaths during 13,938 person-years of follow-
up, and the overall mortality rate was 18.3 (17.6, 19) per 100 person-years. Of all deaths, 
approximately half were liver-related (n=1293, (50.8%)). Just under two-thirds of all deaths 
occurred within one year of diagnosis (n=1513, 59.4%), and again around half were liver-
related (n=819, 54.1%). Overall, liver-related deaths were greater at all time points than any 
other single cause of death. Mortality in the comparison group was a fifth of that in people 
with cirrhosis, 2.98 (95% CI 2.94, 3.03) per 100 person-years with the most common cause 
of death being circulatory (32.7%) followed by non-liver neoplasm (29.4%), other (24.8%), 
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respiratory (12.5%) and liver (0.7%), the latter being fifty times less than that of people with 
cirrhosis.  
Table 3 shows crude mortality rates stratified by aetiology. For all specified aetiologies, liver-
related death was the most common cause of death. Non-liver neoplastic death was the 
main cause of death amongst patients of unspecified aetiology and the rate was higher than 
that seen in the other aetiology subgroups.  
We have looked at the specific type of liver-related deaths by aetiology. The main difference 
was a significantly higher proportion of people dying due to alcoholic liver disease (ICD-10 
code K709) in the alcohol subgroup compared to the other subgroups. The proportion of 
liver-related deaths due to alcoholic liver disease were 20.2% (n=24), 9.6% (n=10), 42.1% 
(n=384) and 2.5% (n=4) in viral hepatitis, AI/metabolic, alcohol and unspecified aetiology 
groups respectively, (p<0.01). 
 Hepatocellular carcinoma as cause of death 
Of all cases who died, 96 (3.8%) deaths were due to hepatocellular carcinoma (mortality rate 
= 0.68 (95%CI 0.56, 0.84) per 100 person-years), this varied by aetiology ranging from 0.5 
per 100 person-years to 1.5, for patients of alcohol and viral hepatitis aetiology respectively 
(see Table 3). The equivalent hepatocellular carcinoma rate amongst controls was 0.003 
(95%CI 0.002, 0.004).  
Amongst those who died due to a liver-related cause, hepatocellular carcinoma was the 
underlying cause of death for 7.4% (96 out of 1302) and 13.5% (17 out of 126) in those with 
and without liver cirrhosis, respectively. In compensated and decompensated patients, the 
proportion of liver-related deaths attributed to hepatocellular carcinoma was 13.3% and 3.2% 
respectively. 
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Risk of mortality adjusted for competing events 
Table 4 shows the cumulative incidence and excess risk of death by 5 years after diagnosis; 
after adjusting for competing risks, age and sex, and stratified by stage of disease. As the 
pattern for cumulative incidence and excess risk are similar we have focused on the latter.  
In compensated patients, the excess risk of death due to liver-related death was higher than 
non-liver causes of death combined for all aetiologies (apart from unspecified), with those of 
alcoholic aetiology representing the highest excess risk of 30.8% (95%CI [27.9, 33.1]).  This 
compares to an excess risk of all non-liver related deaths combined of only 9.9% in patients 
with alcoholic cirrhosis.   In people with cirrhosis of unspecified aetiology, the excess risk of 
non-liver death was 10.7% (of which 7.7% was attributed to non-liver neoplasm death) and 
that of liver-related mortality was 6.7%. For patients of unspecified aetiology, the three most 
common types of the 181 non-liver related neoplastic deaths were pancreatic (n=32, 17.7%), 
primary site unspecified (n=25, 13.8%) and lung (n=17, 9.4%). 
 
Figure 1 displays the excess risk of death compared to those without liver cirrhosis, in 
compensated patients, at every time point up to 5 years, for each aetiology subgroup. The 
figure highlights clearly that at every time point, liver-related death is associated with the 
highest excess risk in those with viral hepatitis, autoimmune/metabolic and alcohol aetiology. 
Whereas those of unspecified aetiology have a higher excess risk of non-liver causes of 
death combined throughout the five years post diagnosis, than that of liver-related cause of 
death. 
In decompensated patients, the excess risk of death due to liver-related reasons was higher 
than any other cause of death, for all aetiologies and all 95% confidence intervals for liver-
related excess mortality excluded zero (Table 4).  
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Figure 1: Excess risk of mortality following diagnosis in 
compensated patients by aetiology, adjusting for age, sex and 
competing events. 
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Subgroup analysis: smoking status 
Supplementary Tables 1 and 2 show the cumulative incidence and excess mortality by 
aetiology for ever-smokers and non-smokers respectively. There was a similar pattern to that 
without stratification by smoking status. For example in compensated patients, the highest  
excess of non-liver neoplasm death was seen in patients of unspecified aetiology, in both 
ever-smokers (9.24%, 95%CI [7.67, 10.81]) and non-smokers (5.87%, 95%CI [4.68, 7.05]).  
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DISCUSSION 
Main findings 
We have demonstrated how cause of death in people with cirrhosis varies by the underlying 
aetiology of liver disease and stage of disease. After adjusting for competing risks, people 
with compensated and decompensated cirrhosis of alcohol, viral hepatitis and 
autoimmune/metabolic aetiology, were more likely to die from liver-related causes than any 
other cause of death, when compared to the general population. In particular, people of 
alcohol aetiology had the highest 5-year excess risk of liver-related death compared to any 
other compensated aetiology subgroup. Importantly however, people with unspecified 
cirrhosis who were compensated at diagnosis had a higher excess risk of non-liver death 
than liver-related death.  
Most of the non-liver related deaths in compensated unspecified cirrhosis patients were due 
to non-liver neoplastic deaths that occurred independently of smoking status. Knowledge of 
the risk of non-liver neoplasm (particularly pancreatic) during an early stage of disease 
should provide an opportunity for clinicians to be vigilant when reviewing these patients. 
 
Strengths/Limitations 
Our study has the advantages of its large size, general population setting, adjustment for 
competing risks and a design which minimizes selection bias. An important limitation to 
consider is the potential of misclassification with respect to identifying patients’ aetiology 
which is crucial to discuss given that it is our primary exposure variable.  It is possible, for 
example, that we have underreported, to some degree, the number of people with alcohol 
aetiology both owing to our imposed hierarchy of aetiologies and as reporting of alcohol 
consumption in medical notes is known not to reflect true alcohol consumption.[21]  
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However, we are confident that using a combination of both primary and secondary care 
healthcare records has provided us with as much information as would be obtained if we 
were to conduct a case-note review. For the aetiologies which are diseases we expect these 
to have a high specificity as a recent study has reported high validation for the diagnosis of 
autoimmune hepatitis in the CPRD [24] and additionally a systematic review showed that the 
validation of many other diagnoses recorded in the CPRD was high.[25] Compared to other 
published studies in the UK [6,8,16] it would appear that our coverage of aetiology (i.e. the 
proportion of each type of subgroup) is as good, if not better, probably because we are the 
first study to use linked databases and hence multiple healthcare records.   Despite the large 
size of our cohort, we were unable to carry out subgroup analyses among those with multiple 
aetiologies for example viral hepatitis and alcohol. Had we used more than four subgroups 
this would have resulted in lack of power and imprecision due to small numbers of events 
(deaths). In addition, it is likely that there would be some misclassification of the joint 
aetiologies and that coupled with the small numbers of events would mean that we would be 
unable to accurately assess the relationships with cause-specific deaths.  The main 
limitation of having four mutually exclusive categories is that the liver-related mortality rates 
we have provided in our viral hepatitis and AI/metabolic aetiology subgroups may be 
overestimates of the true risk in those with a single aetiology. 
 
 
 Another limitation is potential ascertainment bias. It is possible that there is a recording bias 
with doctors filling in death certificates more likely to record liver disease as the cause of 
death in patients known to have liver cirrhosis compared to those without cirrhosis. 
Furthermore, it is well documented that cause of death information taken from death 
certificates is often lacking in accuracy and completeness. Diagnostic and coding errors 
often occur and multiple disease processes can mask the true underlying causes of 
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death.[26] However, ONS data based on WHO guidelines is the most pragmatic and only 
feasible method to ascertain cause of death in a standardised way for such a large study 
population. In addition, a recent study has shown that misclassification of cause of death 
may only bias estimates in patients older than 85, a small proportion of our study cohort 
(n=183, 3.6%).[21] Finally, underlying cause of death was used to avoid the possible effect 
of changes in coding requirements over time.[27] 
There may be some misclassification with respect to stage of disease. In the UK, once a 
patient is diagnosed with cirrhosis they do not necessarily always receive surveillance 
therefore assigning stage of disease around diagnosis is imprecise. It is possible that we 
have underestimated the number of people diagnosed with decompensated cirrhosis, 
however we have minimized this as best we can by identifying the first clinical symptom up 
to one year before the diagnosis date; thus taking into account that diagnosis date may not 
be when the person first became symptomatic. Finally, by calculating cumulative incidence, 
and therefore adjusting for competing events, we have minimized the likelihood of over 
estimating the risk of death for each specific cause. 
 
Comparison with other studies  
Our study is probably best compared with a large Danish nationwide cohort study which 
identified 10,154 patients with liver cirrhosis admitted to hospital during the period 1982-
1989.[9] Of the 69% of patients who died by 1993, 51% of deaths were attributed to causes 
related to cirrhosis (similar to this current study).  
Also, similar, the non-specified cirrhosis group had a greater excess risk of cancer-related 
death (Standardized Mortality Ratio (SMR) of 8.8), than the alcoholic cirrhosis group (SMR 
of only 4.9). When comparing the cause-specific risks of death with the general population 
the authors have not reported absolute risk of death which limits the practical translation of 
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their figures into the clinical arena.  One further limitation, as mentioned by the authors, is 
lack of lifestyle data such as smoking status which they have not been able to adjust for. 
A commonly referenced study describing the cause-specific mortality in patients with 
cirrhosis in the UK is the afore-mentioned paper by Roberts et al. which used data from 
hospital discharge statistics in the Oxford region during 1968 to 1999.[8] The authors 
included patients admitted for any chronic liver disease (ICD-10 K70, K73, K74, K76.0) a 
much broader case definition than our specific measure of cirrhosis diagnosis including 
patients who do not necessarily have cirrhosis, for example people with alcoholic liver 
disease (K70.9). After following patients up to one year, they found that liver disease was the 
certified underlying cause of death for 51% of patients who died, similar to our study 
(53.8%). Cause-specific SMRs by aetiology were determined and, also similar to our 
findings, the unspecified cirrhosis subgroup had a higher relative risk of death from 
neoplastic causes (SMR 9.6) than the alcoholic subgroup (3.2), and all other aetiology 
subgroups. Those people with cirrhosis of alcoholic aetiology had a higher SMR for liver-
related mortality compared to all other aetiology subgroups. However unlike our findings, the 
SMR for liver-related death was higher than non-liver related deaths combined for the 
unspecified group. The authors did not have access to clinical or demographic data therefore 
they were unable to categorise patients by severity of cirrhosis or smoking status, as has 
been done in the present study, and therefore we cannot make a direct comparison with 
some of the figures we have displayed.  
We found that 3.8% of all deaths were due to hepatocellular carcinoma and rates varied 
from 0.5 per 100 person- years to 1.5, for patients of alcohol and viral hepatitis aetiology 
respectively.  In 2012 Jepsen et al. conducted a registry-based study similar to ours and 
reported an annual hepatocellular carcinoma incidence rate of 0.4% (95% CI 0.34% to 
0.47%) in patients exclusively with alcoholic cirrhosis, diagnosed between 1993 and 2005 in 
Denmark.[28] Sorensen et al determined hepatocellular carcinoma risks among people with 
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cirrhosis in Denmark between 1977 and 1989.[29] Their rates of hepatocellular carcinoma  
were slightly lower than ours (0.34 and 0.25 per 100 person years for alcohol and 
unspecified cirrhosis respectively). Other studies from Europe, Japan and America report 
substantially higher rates of hepatocellular carcinoma.[30-34] Our rates therefore are not that 
dissimilar from equivalent database epidemiological studies from Denmark to which our work 
is probably best compared. 
 
 
Clinical implications 
Predicting future mortality rates is important as such knowledge may enable improved 
planning of health services and prioritization of limited public health resources. For example, 
the finding that the alcohol aetiology group had  the highest excess risk of liver-related death 
compared to the other subgroups, when diagnosed at early stage of disease, and given the 
rise in the occurrence of alcohol-related cirrhosis previously reported,[1,2] implies that the 
planning of future services should allow for the number of people requiring liver services in 
England and other countries. Given that the most common liver-related death amongst those 
with alcohol cirrhosis is alcoholic liver disease, this highlights the importance of attempting to 
reduce alcohol consumption and the development of other interventions in this regard.  For 
example, including alcohol consumption in the Quality Outcomes Framework may lead to 
better recording of alcohol in the UK (as in the case of smoking,[35]) and ultimately the 
identification of patients at high risk of liver disease and interventions to reduce future 
cirrhosis development 
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We have determined that compensated patients of unspecified aetiology had an excess risk 
of non-liver related neoplasm compared to the general population. There are several 
possible reasons for this excess mortality. Firstly, whilst we have shown that the excess is 
not due to differences in distributions of age, sex and smoking status between people with 
cirrhosis and those without the disease; the excess non-liver neoplasm mortality between 
these two groups could be due to residual confounding. For example, social deprivation has 
recently been associated with cancer mortality.[36] With respect to the association between 
the incidence of cirrhosis and socio-economic class, the current literature is limited, but if a 
positive relationship does exist then differences in deprivation between those with and 
without cirrhosis could explain some of the excess we report. Future research is required to 
investigate the effect of deprivation on excess mortality. 
Secondly, as patients with cirrhosis of unspecified aetiology undergo several tests (similar to 
those used to detect cancer) these patients are consequently likely to have more incidental 
findings, of say non-specific and pancreatic cancer, compared to those without cirrhosis. 
Ascertainment bias, therefore, may explain why people with unspecified cirrhosis are at 
higher risk of dying from cancer compared to the general population.  
Thirdly, patients with cirrhosis are known to have comorbidities which may influence excess 
mortality.[37] However, statistically, we cannot adjust for particular comorbidities as they are 
part of the final common pathway to the specific causes of death. For example, myocardial 
infarction and congestive heart failure are comorbidities that are necessary for the outcome 
of circulatory death and therefore should not be treated as confounders in the context of our 
study. 
It is biologically plausible that people with unspecified cirrhosis may truly be of higher risk of 
non-liver neoplasm than those without the disease of similar age and sex. It has long been 
reported that cryptogenic cirrhosis (analogous to our unspecified group) is associated with 
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non-alcohol fatty liver disease[38] which in turn is related to obesity, and there are several 
prospective epidemiological studies which have demonstrated a direct association between 
being overweight and risk of cancer.[39,40] It has been estimated that about 20% of cancers 
are caused by excess weight.[40] Therefore the excess neoplastic death we find in 
compensated unspecified patients may be explained by a higher level of obesity present in 
those with unspecified cirrhosis than those without the disease of similar age and sex. 
However, we cannot test for this inference statistically as it may be misleading to adjust for 
patients’ weight, as timing of measurement may be influenced by disease stage. For 
example, patients are likely to have been first weighted with cirrhosis at their presentation or 
decompensation and therefore could be overweight due to having ascites or those with 
cancer could lose weight dramatically due to cancer cachexia or the effects of 
chemotherapy.  
 
Conclusion 
In summary, our study has described the cause-specific mortality of a comprehensive and 
heterogeneous population of people with cirrhosis in England. The causes of excess death 
in people with liver cirrhosis vary by underlying cause of liver disease and stage of disease. 
Patients of alcoholic cirrhosis, chronic viral hepatitis and autoimmune/metabolic aetiology 
are at higher risk of liver-related death than any other cause of death, and compensated 
unspecified patients are at higher risk of non-liver neoplastic death, when compared to the 
general population, up to five years post-diagnosis. In order to reduce premature mortality 
amongst people with liver cirrhosis, patients’ care pathways need to be tailored depending 
on aetiology and stage of disease. 
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